3208-25-1

Basic information

• Product Name: 7-PHENYL-1-HEPTANOL
• Synonyms: 7-PHENYL-1-HEPTANOL;7-Phenylheptane-1-ol;7-Phenylheptyl alcohol;7-phenylheptan-1-ol;Benzeneheptanol
• CAS NO: 3208-25-1
• Molecular Formula: C₁₃H₂₀O
• Molecular Weight: 192.3
• Mol File: 3208-25-1.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 115-117°C 0,5mm
• Flash Point: 115-117°C/0.5mm
• Appearance: colourless liquid
• Density: 0,962 g/cm3
• Vapor Pressure: 0.000293mmHg at 25°C
• Refractive Index: 1.5080
• PKA: 15.19±0.10(Predicted)
• Stability: Stable. Combustible. Incompatible with strong oxidizing agents.
• BRN: 1865431
• CAS DataBase Reference: 7-PHENYL-1-HEPTANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 7-PHENYL-1-HEPTANOL(3208-25-1)
• EPA Substance Registry System: 7-PHENYL-1-HEPTANOL(3208-25-1)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 3208-25-1(Hazardous Substances Data)

Usage

Chemical Properties

colourless liquid

InChI:InChI=1/C13H20O/c14-12-8-3-1-2-5-9-13-10-6-4-7-11-13/h4,6-7,10-11,14H,1-3,5,8-9,12H2

Upstream product

• 101689-18-3 7-phenylheptanoic acid methyl ester 
• 925-90-6 ethylmagnesium bromide 
• 627-30-5 1-chloro-3-hydroxypropane 
• 717-21-5 3-(furan-1-yl)-1-phenyl-prop-2-en-1-one 
• 201230-82-2 carbon monoxide 
• 536-74-3 phenylacetylene 
• 6654-36-0 methyl 6-oxohexanoate 
• 53963-10-3 2-[(6-bromohexyl)oxy]tetrahydro-2H-pyran 
• 4286-55-9 1-bromo-6-hexanol 
• 629-11-8 1,6-hexanediol 
• 1443544-29-3 C₁₈H₂₈O₂ 
• 134511-26-5 7-phenylheptanoic acid ethyl ester 
• 5631-95-8 2,3-dichlorotetrahydro-2H-pyran 
• 40228-90-8 7-phenylheptanoic acid 

Downstream Products

• 101689-22-9 1-(2,6-Dimethoxybenzoyl)-8-phenyloctane 
• 101689-21-8 1-(2,6-Dimethoxybenzoyl)-8-phenyl-oct-1-ene 
• 101689-19-4 Triphenyl-(7-phenyl-heptyl)-phosphonium; bromide 
• 133839-74-4 (E)-1-(2-Benzyloxy-6-hydroxyphenyl)-9-phenyl-2-nonen-1-one 
• 133839-67-5 1-(2-Benzyloxy-6-hydroxyphenyl)-3-hydroxy-9-phenylnonan-1-one 
• 1101136-32-6 2-hydroxy-8-phenyloctanenitrile 
• 1234334-57-6 2-[2-hydroxy-8-phenyloctyl]-6-methoxy-3,5-dimethyl-4H-pyran-4-one 

Relevant articles and documents

DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC)

This present disclosure relates to protein kinase C (PKC) modulating compounds, methods of treating a subject with cancer using the compounds, and combination treatments with a second therapeutic agent.

Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA)

The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

Design, Synthesis, and Antibacterial Activity of Demethylvancomycin Analogues against Drug-Resistant Bacteria

Five novel N-substituted demethylvancomycin derivatives were rationally designed and synthesized by using a structure-based approach. The invitro antibacterial activities against methicillin-resistant Staphylococcus aureus (MRSA), gentamicin-resistant Enterococcus faecalis (GRE), methicillin-resistant Streptococcus pneumoniae (MRS), and vancomycin-resistant Enterococcus faecalis (VRE) were evaluated. One of the compounds, N-(6-phenylheptyl)demethylvancomycin (12a), was found to exhibit more potent antibacterial activity than vancomycin and demethylvancomycin. Compound 12a was also found to be ～18-fold more efficacious than vancomycin against MRSA; however, the two compounds were found to have similar efficacy against MRS. Furthermore, compound 12a exhibited a favorable pharmacokinetic profile with a half-life of 5.11±0.52h, which is longer than that of vancomycin (4.3±1.9h). These results suggest that 12a is a promising antibacterial drug candidate for further preclinical evaluation.